United Therapeutics Corp

Insight: CFO Edgemond James’ May 18 insider option exercise shows strong confidence in United Therapeutics’ 83% YTD rally, suggesting a bullish long‑term stance for investors.

United Therapeutics CEO’s 10‑b‑5‑1 trades show strategic rebalancing and confidence—buy low, sell high—while keeping a long‑term stake for investors.

United Therapeutics insider trades reveal a strategic 10‑b‑5‑1 plan: executives buying low, selling high to fund R&D and acquisitions while signaling long‑term confidence in its prostacyclin pipeline.

Insider buying at United Therapeutics shows executives remain bullish on future growth, even amid modest price swings and a solid pipeline of inhaled therapies.

Discover how United Therapeutics’ 10(b)(5)(1) plan fuels steady cash flow, stable insider ownership, and minimal market impact—insights for investors.

CEO Martine Rothblatt’s latest 10‑b‑5‑1 trade shows routine insider liquidity moves—buying 9,500 shares while selling options, a subtle signal for investors to watch future earnings impact.

United Therapeutics insider trading shows CEO Martine Rothblatt’s disciplined option sales and shares purchases, underscoring confidence in UTX’s biotech pipeline and stable valuation.

United Therapeutics insider trading shows a routine 10(b5‑1) plan by CEO Rothblatt, signaling steady confidence and no sudden price shift—solid for investors.

Insider trading at United Therapeutics shows disciplined 10b5‑1 plan buying and selling—CEO Rothblatt’s moves confirm confidence in the company’s $560‑$570 price range while underscoring strong insider ownership and future pipeline prospects.

United Therapeutics CFO’s disciplined 10(b)(5)(1) trades reveal insider confidence—steady buys and sells around $570 support long‑term value.